[go: up one dir, main page]

WO2009066181A3 - Oral delayed-release duloxentine hydrochloride pellets - Google Patents

Oral delayed-release duloxentine hydrochloride pellets Download PDF

Info

Publication number
WO2009066181A3
WO2009066181A3 PCT/IB2008/003741 IB2008003741W WO2009066181A3 WO 2009066181 A3 WO2009066181 A3 WO 2009066181A3 IB 2008003741 W IB2008003741 W IB 2008003741W WO 2009066181 A3 WO2009066181 A3 WO 2009066181A3
Authority
WO
WIPO (PCT)
Prior art keywords
duloxentine
release
oral delayed
hydrochloride pellets
pellets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/003741
Other languages
French (fr)
Other versions
WO2009066181A2 (en
Inventor
Perez Sergio Lloret
Pena Agnes Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combino Pharm SL
Original Assignee
Combino Pharm SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm SL filed Critical Combino Pharm SL
Publication of WO2009066181A2 publication Critical patent/WO2009066181A2/en
Publication of WO2009066181A3 publication Critical patent/WO2009066181A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to oral delay ed-re lease pellets of duloxetine hydrochloride. The invention further includes processes for their preparation and utilization.
PCT/IB2008/003741 2007-07-09 2008-07-09 Oral delayed-release duloxentine hydrochloride pellets Ceased WO2009066181A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92969707P 2007-07-09 2007-07-09
US60/929,697 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009066181A2 WO2009066181A2 (en) 2009-05-28
WO2009066181A3 true WO2009066181A3 (en) 2009-08-20

Family

ID=40667910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003741 Ceased WO2009066181A2 (en) 2007-07-09 2008-07-09 Oral delayed-release duloxentine hydrochloride pellets

Country Status (2)

Country Link
AR (1) AR067502A1 (en)
WO (1) WO2009066181A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376095B1 (en) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. ENERGY PELLETS OF DULOXETINE.
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
PL224543B1 (en) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Duloxetine enteric tablet

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693282A2 (en) * 1994-07-18 1996-01-24 Eli Lilly And Company Duloxetine enteric pellets
WO1997033880A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
EP1640000A2 (en) * 2002-11-27 2006-03-29 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
WO2007034503A2 (en) * 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693282A2 (en) * 1994-07-18 1996-01-24 Eli Lilly And Company Duloxetine enteric pellets
WO1997033880A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
EP1640000A2 (en) * 2002-11-27 2006-03-29 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
WO2007034503A2 (en) * 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANSEN P J ET AL: "CHARACTERIZATION OF IMPURITIES FORMED BY INTERACTION OF DULOXETINE HCI WITH ENTERIC POLYMERS HYDROXYPROPYL METHYLCELLULOSE ACETATE SUCCINATE AND HYDROXYPROPYL METHYLCELLULOSE PHTHALATE", JOURNAL OF PHARMACEUTICAL SCIENCE, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 87, no. 1, 1 January 1998 (1998-01-01), pages 81 - 85, XP000891949, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2009066181A2 (en) 2009-05-28
AR067502A1 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
IL194877A0 (en) Duloxetine hydrochloride delayed release formulations
ZA200905012B (en) Process for the preparation of certain substituted sulfimines
IL210549A (en) Substituted- quinoxaline-type bridged-piperidine compounds, compositions comprising them and uses thereof for the manufacture of medicaments
EP2240173A4 (en) Delayed release pharmaceutical composition of duloxetine
WO2010056656A3 (en) Preparation of crystalline palonosetron hydrochloride
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2010129636A3 (en) Lenalidomide polymorph
WO2010065586A3 (en) Preparation of capecitabine
PL2229062T3 (en) A process for the preparation of a hydrolysate
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
ZA200901083B (en) Modified release pharmaceutical composition of bupropion hydrochloride
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
PL2044099T3 (en) Process for the preparation of s-fluoromethyl-6 ,9 -difluoro-11 -hydroxy-16 -methyl-17 -propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
WO2011023954A3 (en) Polymorphic forms of manidipine
EP2111285B8 (en) A method for the preparation of a reducing agent composition
ZA200808011B (en) Process for the isolation of calliterpenone (16alpha, 17-DiHyDroxy-S-Oxo-Phyllocladane)
WO2009066181A3 (en) Oral delayed-release duloxentine hydrochloride pellets
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
WO2008104957A3 (en) Novel polymorphic forms of milnacipran hydrochloride
ZA200901556B (en) Process for the preparation of abacavir
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
IL200951A0 (en) Aryl-sulphonamid compounds, compositions comprising the same, processes for the preparation of the same and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08851213

Country of ref document: EP

Kind code of ref document: A2